Nathan D Seligson
Nathan D Seligson
Assistant Clinical Professor, University of Florida
Bestätigte E-Mail-Adresse bei ufl.edu - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Integration of EMT and cellular survival instincts in reprogramming of programmed cell death to anastasis
S Chakraborty, KB Mir, ND Seligson, D Nayak, R Kumar, A Goswami
Cancer and Metastasis Reviews 39 (2), 553-566, 2020
152020
BRCA1/2 functional loss defines a targetable subset in leiomyosarcoma
ND Seligson, EA Kautto, EN Passen, C Stets, AE Toland, SZ Millis, ...
The oncologist 24 (7), 973, 2019
152019
Degree of MDM2 amplification affects clinical outcomes in dedifferentiated liposarcoma
KLJ Bill, ND Seligson, JL Hays, A Awasthi, B Demoret, CW Stets, ...
The oncologist 24 (7), 989, 2019
112019
Developing drugs for tissue agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine
ND Seligson, TC Knepper, S Ragg, CM Walko
Clinical Pharmacology & Therapeutics, 2020
102020
Evaluating the impact of the addition of cladribine to standard acute myeloid leukemia induction therapy
ND Seligson, ALV Hobbs, JM Leonard, EL Mills, AG Evans, S Goorha
Annals of Pharmacotherapy 52 (5), 439-445, 2018
82018
Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives
MM Faheem, ND Seligson, SM Ahmad, RU Rasool, SG Gandhi, M Bhagat, ...
Cell death discovery 6 (1), 1-12, 2020
62020
Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma
ND Seligson, CW Stets, BW Demoret, A Awasthi, N Grosenbacher, ...
Oncotarget 10 (55), 5671, 2019
62019
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity
ND Seligson, JL Warner, WS Dalton, D Martin, RS Miller, D Patt, KL Kehl, ...
Journal of the American Medical Informatics Association 27 (11), 1808-1812, 2020
52020
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer
JM Seligson, AM Patron, MJ Berger, RD Harvey, ND Seligson
Annals of Pharmacotherapy, 1060028020966548, 2020
42020
XRCC1‐mediated DNA repair is associated with progression‐free survival of multiple myeloma patients after autologous stem cell transplant
AK Persaud, J Li, JA Johnson, N Seligson, DW Sborov, E Duah, YK Cho, ...
Molecular carcinogenesis 58 (12), 2327-2339, 2019
32019
Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma
ND Seligson, A Awasthi, SZ Millis, BK Turpin, CF Meyer, A Grand'Maison, ...
JAMA network open 2 (10), e1912416-e1912416, 2019
32019
UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation
RS Nelson, ND Seligson, S Bottiglieri, E Carballido, AD Cueto, I Imanirad, ...
Cancers 13 (7), 1566, 2021
12021
Evaluation of the timing of MRSA PCR nasal screening: How long can a negative assay be used to rule out MRSA-positive respiratory cultures?
SC Turner, ND Seligson, B Parag, KM Shea, ALV Hobbs
American Journal of Health-System Pharmacy 78 (Supplement_2), S57-S61, 2021
2021
Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target
ND Seligson, RD Maradiaga, CM Stets, HM Katzenstein, SZ Millis, ...
NPJ precision oncology 5 (1), 1-11, 2021
2021
Adding the second T: Elevating STAR to START for behavioral interviewing
JM Apple, JC Guerci, ND Seligson, SD Curtis
American Journal of Health-System Pharmacy 78 (1), 18-21, 2021
2021
Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation
J Li, N Seligson, X Zhang, J Johnson, Z Vangundy, D Wang, M Phelps, ...
Anticancer Research 40 (10), 5707-5713, 2020
2020
Histone H3 modifying genes may serve as a predictive marker for metastasis in synovial sarcoma.
A Awasthi, ND Seligson, SZ Millis, JL Hays, JL Chen
Journal of Clinical Oncology 37 (15_suppl), 11058-11058, 2019
2019
Genomic amplification of CDK4 in dedifferentiated liposarcomas as a predictive biomarker for microtubule disrupting agents.
B Demoret, A Rogers, ND Seligson, EA Kautto, JL Hays, JL Chen
Journal of Clinical Oncology 36 (15_suppl), 11581-11581, 2018
2018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–18